Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cells
Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cells
复制标题
DOI：
10.1097/qad.0b013e328012b85f
复制
发表时间：
2007-01-30
期刊：
影响因子：
3.8
通讯作者：
Montaner, Luis J.
中科院分区：
文献类型：
--
作者：
Azzoni, Livio;Chehimi, Jihed;Montaner, Luis J.
目的：抗逆转录病毒治疗后先天免疫效应物的恢复动力学是unknown.Design and methods：多个连续冻存样品（病毒血症和ART抑制）从66例患者参加妇女的跨机构艾滋病毒研究或多中心艾滋病队列研究队列（中位随访，700天）进行了分析，以确定自然杀伤细胞，树突状细胞和T细胞的变化，流式细胞术。还在样品的子集中测量功能参数。随时间推移的变化进行了分析的混合效应模型的基础上，一个单一的结在270 days.Results：病毒抑制后，CD 4和白色血细胞计数和T细胞活化下降的快速上升得到证实。然而，治疗270天后自然杀伤细胞亚群增加，基线CD4%呈负效应。CD 123+浆细胞样而非髓样树突状细胞在前270天内呈增加趋势，基线CD4%具有积极作用;浆细胞样树突状细胞诱导的干扰素-α产生在随访结束时显著增加。自然杀伤细胞和浆细胞样树突状细胞恢复的动力学与T细胞亚群的动力学明显不同，表明抑制方案的早期和延迟益处。(c)2007年利平科特威廉姆斯&威尔金斯。
Objective: The kinetics of recovery for innate immune effectors following antiretroviral therapy are unknown.Design and methods: Multiple sequential cryopreserved samples (viremic and ART-suppressed) from 66 patients enrolled in the Women's Interagency HIV Study or Multicenter AIDS Cohort Study cohorts (median follow-up, 700 days) were analyzed to determine natural killer, dendritic and T-cell changes by flow cytometry. Functional parameters were also measured in a subset of samples. Changes overtime were analyzed by mixed-effect modeling based on a linear spline with a single knot at 270 days.Results: Following viral suppression, a rapid rise in CD4 and white blood cell counts and a decline in T-cell activation were confirmed. However, natural killer cell subsets increased after 270 days of therapy, with a negative effect by baseline CD4%. CD123+ plasmacytoid but not myeloid dendritic cells showed a trend to increase during the first 270 days with a positive effect of baseline CD4%; plasmacytoid dendritic cell-induced interferon-alpha production significantly increased by end of follow-up.Conclusions: The kinetics of natural killer and plasmacytoid dendritic cell recovery are markedly different from those of T-cell subsets, indicative of early and delayed benefits of suppressive regimens. (c) 2007 Lippincott Williams & Wilkins.